$TWST

Cho Dennis sold $28K of TWST

Cho Dennis (See Remarks) sold 402 shares of Twist Bioscience Corp (TWST) at $69.84 on 2026-06-08.

Original reporting
SEC EDGAR · Cho Dennis
Published Jun 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

Because it’s a routine insider transaction without accompanying corporate news, it mainly affects sentiment rather than valuation drivers.

02

Market read

Traders may note the insider selling signal, but the disclosed value is modest and not a standalone catalyst.

03

What to watch

The transaction size is small relative to typical institutional flows, and the filing timing may not coincide with any fundamental catalyst.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-10 for a 2026-06-08 sale

Background

The article is a primary-source SEC Form 4 disclosure reporting an officer’s open-market sale of Twist Bioscience shares.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience insider Dennis Cho filed an open-market sale of 402 shares at $69.8442 on 2026-06-08 (Form 4).

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The disclosure is a routine Form 4 insider transaction with modest dollar value ($28k) and no stated linkage to a new corporate event.

Market effects

No clear read-across to biotech tools/insider behavior beyond routine governance signals.

None.

None.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; the lack of a 10b5-1 plan doesn’t necessarily imply bearish conviction.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale disclosure.

  • Dennis Cho

    Officer who sold 402 shares on 2026-06-08.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.